Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. [electronic resource]
Producer: 20140807Description: 2816-24 p. digitalISSN:- 1538-7445
- Angiogenesis Inhibitors -- administration & dosage
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- blood supply
- Cell Line, Tumor
- Drug Synergism
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms -- blood supply
- Male
- Mass Spectrometry
- Mice
- Mice, Nude
- Multimodal Imaging
- Phthalazines -- administration & dosage
- Piperidines -- administration & dosage
- Positron-Emission Tomography
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Quinazolines -- administration & dosage
- Receptors, Platelet-Derived Growth Factor -- antagonists & inhibitors
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.